Effect of Konjac-mannan in Individuals With Insulin-Resistance Syndrome

Beneficial Effects of Viscous Dietary Fiber From Konjac-Mannan in Subjects With the Insulin Resistance Syndrome

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03741686

Enrollment

Registered

2018-11-15

Start date

1991-01-31

Completion date

1999-06-30

Last updated

2018-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Resistance Syndrome

Keywords

insulin resistance syndrome, fiber, konjac

Brief summary

To study whether a diet high in fiber from Konjac-mannan (KJM) has an effect on metabolic control in individuals with insulin resistance syndrome.

Interventions

DIETARY_SUPPLEMENTkonjac glucomannan

Konjac-mannan fiber-enriched biscuits (0.5 g/412KJ \[100kcal\] of glucommanan)

DIETARY_SUPPLEMENTwheat bran

Wheat bran (hard red wheat bran) fiber enriched biscuits

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

45 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Impaired glucose tolerant * Clinical absent of CHD * BMI less than 30 kg/m2 * Presence of full insulin resistance syndrome * Reduced HDL cholesterol * Elevated serum triglycerides * Moderate hypertension

Exclusion criteria

* Regular smoking * Regular alcohol consumption * Family history of premature coronary heart disease * Hypothyroidism * Renal, hepatic or gastrointestinal disease * Taking medications for hyperglycemia * Taking medications for hyperlipidemia * Taking medications for hypertension

Design outcomes

Primary

Measure	Time frame
change in total:HDL cholesterol	change from baseline after 3 weeks, relative to control
change in fructosamine	change from baseline after 3 weeks, relative to control
change in systolic blood pressure	change from baseline after 3 weeks, relative to control

Secondary

Measure	Time frame
change in apolipoprotein A-1	change from baseline after 3 weeks, relative to control
change in apolipoprotain B	change from baseline after 3 weeks, relative to control
change in glucose	change from baseline after 3 weeks, relative to control
change in total cholesterol	change from baseline after 3 weeks, relative to control
change in diastolic blood pressure	change from baseline after 3 weeks, relative to control
change in body weight	change from baseline after 3 weeks, relative to control
change in apoB:ApoA-1	change from baseline after 3 weeks, relative to control
change in insulin	change from baseline after 3 weeks, relative to control
change in LDL cholesterol	change from baseline after 3 weeks, relative to control
change in HDL cholesterol	change from baseline after 3 weeks, relative to control

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026